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Abstract
Objectives—Eosinophilic esophagitis (EoE) is becoming increasingly more common, but the 
prevalence of other eosinophilic gastrointestinal disorders (EGIDs) is unknown. Our objective was 
to estimate the prevalence of eosinophilic gastritis, gastroenteritis, and colitis in the U.S..
Methods—We used the IMS Health LifeLink™, PharMetrics Plus™Claims Database, data 
representative of a U.S. national commercially-insured population containing medical and 
pharmaceutical claims for >75million individuals. We restricted our sample to patients age 0–64 
with continuous enrollment between 7/1/2009–6/30/2011. We identified cases of eosinophilic 
gastritis, gastroenteritis, and colitis as defined by ≥1 instance of the ICD-9 codes 535.70, 558.41, 
and 558.42, respectively. We calculated the prevalence of the codes in the database and then 
standardized the estimates to the U.S. population by age and sex.
Results—The standardized estimated prevalences of eosinophilic gastritis, gastroenteritis, and 
colitis were 6.3/100,000, 8.4/100,000, and 3.3/100,000, respectively. The prevalence of 
eosinophilic gastroenteritis was highest among children age < 5 years, whereas eosinophilic 
gastritis was more prevalent among older age groups. We observed no age differences for 
eosinophilic colitis. Among affected patients there was a high proportion of co-existing allergic 
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conditions, 38.5% for eosinophilic gastritis, 45.6% for gastroenteritis, and 41.8% for colitis. 
Concomitant allergic disease was most commonly identified in pediatric patients.
Conclusions—The prevalence of non-EoE EGIDs remains rare in the U.S., with less than 
50,000 total patients affected. There appears to be a female predominance, as well as a high co-
occurrence of atopic comorbidities.
Keywords
eosinophil; prevalence; administrative data; United States
Introduction
Eosinophilic gastrointestinal disorders (EGIDs) are characterized by abnormal eosinophilic 
infiltration of different segments of the GI tract in the absence of an identifiable secondary 
cause. Eosinophilic esophagitis (EoE) is the most common of these conditions, (1–3) with a 
recent prevalence estimate of 57 cases/100,000 persons in the United States. (4) 
Eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic colitis, are thought to be 
less commonthan EoE, although the prevalence of these other EGIDs has not been well-
described.
Many features of these diseases, including atopic comorbidities or clinical presentation, have 
been described only in the setting of case series studies or small, single-center studies. (5–
10) The population-level burden of these diseases, the age- and gender-based distributions, 
and associations with other conditions, are unknown. The potential for estimating the 
prevalence of these other EGIDs, at the national level, was made possible in 2008 with the 
approval of an International Classification of Diseases, Ninth Revision (ICD-9) codes for 
eosinophilic gastritis (535.70), eosinophilic gastroenteritis (558.41), and eosinophilic colitis 
(558.42), but to date there have been no studies utilizing these codes.
The aim of the present study was to use a large health plan claims database to identify and 
characterize cases of eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic 
colitis and estimate the prevalence of each of these EGIDs in the U.S. We also sought to 
characterize the epidemiology of these diseases with respect to age, sex, clinical 
presentation, and concomitant allergic diseases.
Methods
Study design, data source, and case definition
We performed a retrospective analysis of the IMS Health LifeLink™ Claims Database (IMS 
Health Inc.). This database contains longitudinal, integrated, fully-adjudicated medical and 
pharmaceutical claims for over 75 million individuals from over 80 health plans, from all 50 
states in the U.S., and has been shown to be representative of a U.S. national commercially 
insured population. (11, 12) These data are aggregated after a sufficient period of time has 
elapsed to ensure completeness of billing data. Data were not linkable to the patient medical 
record, however enrollees’ demographic data including age, sex, and census region 
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(northeast, south, midwest, and west) were available. Regional designations correspond to 
the U.S. census regions.
We restricted the dataset to subjects continuously enrolled from July 1, 2009 through June 
30, 2011 and estimated a two-year, period prevalence, accounting for the delay in uptake for 
the new code that was noted after its introduction in 2008 and allowing an adequate amount 
of time for the code to be used. (13) We excluded enrollees age 65 years or older as their 
claims data are likely to be incomplete due to coinsurance provided through Medicare.
Eosinophilic gastritis, gastroenteritis, and colitis were defined based on a patient having ≥1 
instance of the ICD-9 codes 535.70, 558.41, and 558.42, respectively. We did not include 
the ICD-9 code of 558.3 as this is a more general code for allergic gastroenteritis and colitis 
and would potentially lead to over estimation of the number of cases. Eosinophilic 
esophagitis cases were identified as described previously, for the purposes of comparison for 
concomitant allergic disease. (4)
Descriptive factors and allergic disease
In addition to the codes for eosinophilic gastritis, gastroenteritis, and colitis, data on other 
ICD-9 diagnostic codes were extracted. These included ICD-9 codes for the atopic disorders 
of rhinitis, sinusitis, dermatitis, urticaria, asthma, and food allergies (Supplementary Digital 
Content – Table 1). Food allergy and other allergic conditions were characterized by at least 
one instance of the use of the corresponding allergic disease related ICD-9 code during the 
study period. Because these allergic conditions could represent prevalent conditions, we did 
not require any accompanying procedure code. We also extracted data on census region of 
residence, sex, and age. Age was characterized in 5-year increments to allow standardizing 
of prevalence estimates to the age and sex distribution of residents in the United States per 
the 2010 Census Data. In each of the non-EoE EGID conditions, we examined the frequency 
of concomitant functional dyspepsia (536.9) and IBS (564.1). Finally, we extracted data on 
ICD-9 codes (Supplementary Digital Content – Table 1) for a number of upper and lower 
gastrointestinal (GI) symptoms of interest.
Statistical analysis
We used descriptive statistics to characterize demographics, symptoms, and concomitant 
allergic diseases, and to estimate the proportion of patients with >1 EGID condition (for 
example, superimposed eosinophilic gastritis and eosinophilic colitis). We also estimated the 
proportion of patients with superimposed EoE, using a previously validated claims-based 
definition for EoE (≥1 instance of the ICD-9 code 530.13). (14) Pearson chi-square tests 
were used to evaluate whether the distributions of sex, age, census region, the presence of 
allergic diseases, and the proportions of upper and lower gastrointestinal symptoms differed 
between EGID cases and the source population.
To calculate period prevalence, we divided the number of patients who met the case 
definition for each EGID during the two year period by the total number of enrolled patients 
during the same two years (the study population). The overall prevalence, prevalence by sex, 
prevalence by census region, and prevalence by 5-year age increments were estimated using 
the source population. We standardized the overall prevalence estimate to the U.S. 
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population by age and sex using 2010 census data for individuals < 65 years of age, to allow 
us to estimate the absolute number of patients with eosinophilic gastritis, gastroenteritis, and 
colitis in the U.S..
We performed sensitivity analyses using more restrictive case definitions for the EGIDs. 
Specifically, we estimated the prevalence of eosinophilic gastritis, gastroenteritis, and colitis 
after excluding patients with ICD-9 codes suggestive of possible competing causes of GI 
tract eosinophilia, including ulcerative colitis (556.x), Crohn’s disease (555.x), and diseases 
with an infectious etiology (ICD-9 codes 120.0–127.9). The University of North Carolina 
Institutional Review Board exempted this study from review.
Results
Characteristics of patients with EGIDs
Of the 11,569,217 persons continuously enrolled during the study period, 774 (0.007%) met 
criteria for eosinophilic gastritis, 954 (0.008%) met criteria for eosinophilic gastroenteritis, 
and just 404 (0.003%) met criteria for eosinophilic colitis.The mean (± std) number of 
claims, on different days, for eosinophilic gastritis, gastroenteritis, and colitis was 1.3 (± 
1.6), 1.7 (± 2.4), and 1.8 (± 3.9) claims, respectively. There were 104 patients with >1 non-
EoE EGID, representing 4.9% of patients with an EGID (101 with 2 conditions and 3 with 
all 3 conditions). Of the 954 patients with eosinophilic gastroenteritis, 51 (5.3%) had 
diagnostic codes for both eosinophilic gastritis and eosinophilic gastroenteritis.The 
proportion of patients with superimposed EoE was similar across conditions, specifically 
10.6% for eosinophilic gastritis, 12.0% for eosinophilic gastroenteritis, and 10.9% for 
eosinophilic colitis. Assessment of the frequency of concomitant functional dyspepsia and 
IBS in each of the non-EoE EGID conditions identified that for eosinophilic gastritis 0.7% 
and 5.6% had co-existing functional dyspepsia and IBS codes, respectively. For eosinophilic 
gastroenteritis, 0.4% and 8.6% had functional dyspepsia and IBS codes, respectively, and for 
eosinophilic colitis, 1.2% had concomitant functional dyspepsia and 13.4% had concomitant 
IBS.
The mean (std) age of patients with eosinophilic gastritis, gastroenteritis, and colitis was 
39.8(± 17.4), 30.2 (±19.9), and 33.5 (± 20.5) years, respectively. The case distribution of age 
(pediatric or adult), census region (northeast, south, midwest, and west), and sex (male or 
female) was statistically different from that of the source population (Table 1).
Upper and lower gastrointestinal symptoms differed according to condition (Table 2). 
Eosinophilic gastritis patients were more likely than patients with eosinophilic 
gastroenteritis or colitis, to have had chest or throat pain. Patients with eosinophilic colitis 
more commonly had presented with diarrhea (41%) and gastrointestinal bleeding (14%). 
However, abdominal pain was present in a high proportion of patients across all conditions, 
and in nearly 60% of those with eosinophilic colitis. For all disease conditions, more than 
one fourth of patients had presented with nausea and/or vomiting. The proportion of upper 
and lower gastrointestinal symptoms was significantly higher than observed in the source 
population (Table 2).
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Co-existing allergic conditions were relatively common in patients with eosinophilic 
gastritis, gastroenteritis, and colitis, at 38.5%, 45.6%, and 41.8% respectively, and these 
comorbidities were significantly higher than in the source population (Supplementary 
Digital Content – Table 2). The most commonly reported allergic condition was rhinitis (28–
30%). Asthma was reported in 16% of patients with eosinophilic gastritis, 19% of patients 
with eosinophilic gastroenteritis, and 15% of patients with eosinophilic colitis 
(Supplementary Digital Content – Table 2). Similar to that which has been documented in 
EoE, (15) the proportion of patients with concomitant allergic disease was higher among 
pediatric patients (age < 19 years). For example, 58.9% of pediatric patients with 
eosinophilic gastritis also had documentation of an allergic condition, compared to 33.6% of 
adults with eosinophilic gastritis. For eosinophilic gastroenteritis, 51.6% of pediatric patients 
had allergic disease compared to 41.8% of adults. With eosinophilic colitis, 52.0% of 
pediatric patients had concomitant allergic disease compared to 35.9% of adults.
Prevalence and distribution of EGIDs in the United States
In the source population the prevalence of eosinophilic gastritis, gastroenteritis, and colitis 
was 6.7, 8.2, and 3.5 cases/100,000, respectively (Table 3). The female predominance for 
disease was most evident for eosinophilic gastritis, where the prevalence for females was 7.9 
cases/100,000 as compared to 5.4 cases/100,000 for males. Regional differences were 
observed for eosinophilic gastritis and gastroenteritis, where the prevalence in the south and 
midwest was nearly twice that of the prevalence in the northeast and west. In contrast, no 
regional difference in prevalence was observed for eosinophilic colitis (Table 3).
Examination of the prevalence, by age and sex, for each of the EGIDs suggested differences 
between the conditions. For eosinophilic gastritis, particularly among females, the 
prevalence increased with age, with a peak prevalence in the oldest age group (14.4 cases/
100,000 in females for ages 60–64 years) (Figure 1A). Eosinophilic gastroenteritis 
prevalence gradually decreased with age, with highest prevalence for both males and 
females in patients under the age of 5 years, 17.6 cases/100,000 and 16.7 cases/100,000 
respectively (Figure 1B). There was little difference in prevalence of eosinophilic colitis by 
age and sex (Figure 1C).
When age- and sex-standardized to the U.S. population, the estimated prevalence of 
eosinophilic gastritis was 6.3/100,000, the prevalence of eosinophilic gastroenteritis was 
8.4/100,000, and the prevalence of eosinophilic colitis was 3.3/100,000. Applying these 
prevalences to the 2010 U.S. population, we estimate there are 16,952 cases of eosinophilic 
gastritis, 22,548 cases of eosinophilic gastroenteritis, and 8,982 cases of eosinophilic colitis, 
for a total of just 48,482 affected individuals between ages 0–64 years in the U.S., during the 
study period.
In sensitivity analyses, where a more restrictive case definition was used to exclude patients 
with possible competing conditions, we observed similar prevalence estimates to those 
obtained using the primary definitions for eosinophilic gastritis and gastroenteritis, but not 
colitis. Eosinophilic gastritis prevalence was 6.0/100,000 after excluding 34 patients with 
inflammatory bowel disease (IBD) codes and 2 patients with infectious disease codes, and 
the prevalence of eosinophilic gastroenteritis was 7.7/100,000, after excluding 72 patients 
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with IBD codes and 8 patients with infectious disease codes. However, nearly 30% of 
patients with eosinophilic colitis had codes for either IBD (n=114) or infectious disease 
(n=6), reducing the prevalence to just 2.4 cases/100,000. Using these more restrictive 
prevalence estimates, an estimated 43,203 individuals are affected by one of these 
conditions in the United States.
Discussion
In the present study, we estimated the prevalence of eosinophilic gastritis, eosinophilic 
gastroenteritis, and eosinophilic colitis in the United States. To our knowledge, estimates of 
the prevalence of each of these conditions in the U.S. have not been directly calculated from 
national level data. Our results indicate that these conditions are rare and much less common 
than EoE. For the first time, we are also able to present age- and sex-specific prevalence for 
these conditions, show a female predominance for eosinophilic gastritis, gastroenteritis, and 
colitis, and demonstrate an association with allergic diseases. Because of the large database 
that we used, we were able to identify many-fold more EGID patients than have been 
described previously.
One other study estimated the overall prevalence of the non-EoE EGIDs using a 
methodology where allergists and gastroenterologists were surveyed about their practice 
data, and the results were extrapolated nationally. (16) They found a prevalence of 
28/100,000 for combined cases of eosinophilic gastroenteritis and eosinophilic colitis, 
higher than our estimate. They also found higher prevalence in the northeast region, whereas 
we found higher prevalence in the south and midwest.
The age distribution of patients in our study suggested that most patients were adults. The 
ability to identify a larger set of cases than previously described, from which age 
distributions could be examined, was a strength of this study. Although often associated with 
young children, the age distribution of eosinophilic colitis was 33.5 and just 11 of the 404 
cases were among children <2 years of age at the time of diagnosis (3 cases were <1 year of 
age). Adult patients with eosinophilic colitis have been described in smaller, single center 
studies, including a recent study of 11 patients with eosinophilic colitis where the mean age 
was 22. (17, 18)
There have been several published case series of patients with EGIDs. (8, 9,19–21) Case 
series from single centers suggest that these EGIDs are associated with significant morbidity 
and that the clinical presentation differs depending on the location of the eosinophilia in the 
GI tract, and the depth of inflammation through the bowel wall.(9, 19, 20)Patients with 
eosinophilic colitis may present with abdominal pain, diarrhea, and rectal bleeding. 
Eosinophilic gastritis and gastroenteritis patients may present with abdominal pain, nausea 
and vomiting.(7–9,20–22) The upper and lower gastrointestinal symptoms described for 
patients in these smaller studies is consistent with the patient symptoms documented in the 
present study.
Our data show that patients with the non-EoE EGIDs have frequent associated atopic 
conditions, though the proportion is not as high as has been previously reported for EoE. 
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(23–25) In our own data, the proportion of non-EoE EGID patients with concomitant EoE 
was also less than the proportion of EoE patients with atopy (Table 3). Several case series or 
single center studies have identified allergic disease comorbidity in many patients with 
eosinophilic gastritis and gastroenteritis.(5, 6,8, 26, 27) In a case series of 42 patients, Zhang 
et al. found that 30% of the patients with eosinophilic gastroenteritis had concomitant 
allergic rhinitis or asthma. (10) Similarly, Caldwell et al. found that 7 of 14 patients 
diagnosed with eosinophilic gastritis tested positive for food or aeroallergens with skin prick 
testing. This same study provided molecular profiling data to support the assertion that 
eosinophilic gastritis is a Th2-assocated disease. (5) Still, some patients with EGIDs have no 
evidence of concomitant allergic disease and there is some suggestion there may be an 
autoimmune component to these diseases. (28, 29) Our finding of increased diagnosis of 
atopy among patients with eosinophilic colitis is a novel finding, possibly a reflection of the 
larger sample from which these association could be examined. It may also be that patients 
with a chronic health condition are more likely to seek care for other co-morbidities and that 
the increased diagnosis of atopic illness is reflecting increased health care utilization among 
these patients.
There are some limitations to the estimates presented. Although this is the first, large-scale 
administrative claims-data approach to estimating the prevalence of these conditions, there 
is the potential that we may have under- or over-estimated the number of cases. Of note, the 
ICD-9 codes for the non-EoE EGIDs have not been validated against other data sources, 
therefore misclassification of identified cases may be possible. Given the rarity of these 
diseases and the relative newness of these diagnostic codes, however, we would hypothesize 
that our estimates are most likely an underestimate of the true number of cases. In our 
previous study validating the ICD-9 code for EoE, we found that it was highly specific, but 
much less sensitive.(14) We would postulate that it would be similarly unlikely for a 
provider to use one of the EGID ICD-9 codes for a patient without an EGID, but cannot 
confirm this in the present study as our claims data are de-identified and not linked to patient 
records. To attempt to account for this potential misclassification, we performed sensitivity 
analyses using a more restrictive coding case definition, excluding patients with codes for 
possible competing conditions. With this, the estimates changed minimally. In addition, the 
validity of our definitions are supported by the observation that the associated symptom 
codes for patients with these disorders are consistent with what is known about the clinical 
presentation of these conditions. Nonetheless, it is important that, to date, there are no 
published guidelines on case definitions for these conditions, so clinical diagnosis of these 
relatively new entities is likely a heterogeneous process as well. While there are some 
investigations assessing eosinophil levels in the GI tract (29) there are no formal cut-points 
for the number of eosinophils in the stomach, small intestine, and colon in the EGIDs, and 
there are no published guidelines as of yet for the diagnosis of these non-EoE EGIDs.
In addition to potential misclassification, we are limited in our analyses to the data captured 
in the claims database. Therefore, we cannot comment on patient race/ethnicity, 
socioeconomic status, practice setting, endoscopic findings, histologic features, or depth of 
involvement in the wall of the GI tract. Time trends and incidence calculations are also not 
possible given the recent introduction of these ICD-9 codes. The patients in this database are 
representative of a commercially insured population. It is possible that some patients are 
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underinsured, and thus less likely to obtain the services necessary to reach a diagnosis, and 
we do not capture patients who are uninsured, on Medicaid, or on Medicare. This could 
result in an under-ascertainment of the number of cases.
The cases examined also represented prevalent cases and use of the diagnostic codes could 
reflect care received during follow-up treatment for the EGID, rather than at initial 
diagnosis. Therefore, we felt that requiring a procedure code for histopathologic 
examination could underestimate case prevalence. It is possible too, that patients may have 
been misclassified as having one EGID, later to be diagnosed with a different condition. The 
proportion of patients with both eosinophilic colitis and an IBD diagnosis may be indicative 
of diagnostic confusion for eosinophilic colitis. We found little evidence to support 
increased functional disorders in patients with an EGID, and minimal overlap in the 
proportion of patients with more than one EGID.
In examining presence of upper and lower gastrointestinal symptoms, we were only able to 
evaluate symptom codes. Furthermore, we did not restrict occurrence of these symptom 
codes to before or on the date on which the claims was made. Therefore, some of these 
symptoms may be unrelated to the EGID diagnosis. However, because these are prevalent 
cases, we anticipate that there may be instances where the gastrointestinal symptom may 
occur after the diagnosis is made. In future studies, with additional years of follow-up after 
introduction of the code, incident cases may be examined and a more complete description 
of presenting symptoms at diagnosis can be ascertained.
There are several strengths of this study, including that we have used a large, national 
database demonstrated to be representative of all patients in the U.S. with commercial 
insurance. (11, 12) This allowed us to present details on the largest population of EGID 
patients yet reported in the literature, as well as make national prevalence estimates 
standardized to the population of the U.S., aged 0–64 years.
In conclusion, we demonstrate that the non-EoE EGIDs are very rare diseases, with 
prevalences ranging from 3.3 to 8.4 cases/100,000, and with fewer than 50,000 people 
affected in the U.S. with one of these conditions. Moreover, we find that the conditions tend 
to be more common in females- and are associated with high upper and lower 
gastrointestinal morbidity. The high proportion of co-existing atopic illness suggests these 
conditions may arise, in some instances, from a similar pathogenesis as EoE. However 
differences in sex ratios (female predominance for these other EGIDs as compared to male 
predominance for EoE) indicates that there may be important pathogenic differences for 
these conditions. As the time since introduction of these diagnostic codes increases, it will 
allow for additional studies to be conducted which examine incidence and prevalence 
changes over time, as well as long term disease sequelae.
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What is known about this subject?
• The prevalence of non-EoE EGIDs is poorly described in the literature.
• The introduction of ICD-9 codes for these conditions provided the opportunity 
to estimate the prevalence of these conditions in the U.S..
What are the new findings and/or what is the impact on clinical practice?
• Eosinophilic gastritis, gastroenteritis, and colitis are rare, with a standardized 
prevalence of 6.3/100,000, 8.4/100,000, and 3.3/100,000, respectively.
• The prevalence of eosinophilic gastroenteritis was highest among children age < 
5 years, whereas eosinophilic gastritis was more prevalent among older age 
groups. We observed no age differences for eosinophilic colitis.
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Figure 1. 
(A) Prevalence of gastritis (cases per 100, 000) in the database between July 1, 2009 through 
June 30, 2011 for those enrolled continuously for 24 months, as stratified by sex (males are 
the black bars and females are the gray bars) and by 5 year increments of age. (B) 
Prevalence of eosinophilic gastroenteritis (cases per 100, 000) in the database between July 
1, 2009 through June 30, 2011 for those enrolled continuously for 24 months, as stratified by 
sex (males are the black bars and females are the gray bars) and by 5 year increments of age. 
(C) Prevalence of eosinophilic colitis (cases per 100, 000) in the database between July 1, 
2009 through June 30, 2011 for those enrolled continuously for 24 months, as stratified by 
sex (males are the black bars and females are the gray bars) and by 5 year increments of age.
Data source: IMS Health LifeLink™, PharMetrics Plus™Health Plan Claims Database, 
January 2001–November 2011, IMS Health Incorporated. All Rights Reserved.
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